2013 Revenue: $876 million
Tecfidera came out of the gates to high expectations, and still sales burned past expectations all along the way. Released in April 2013, it racked up its $876 million in sales in 8 months. In the first 6 months of this year, it has generated $1.2 billion in sales, allowing the Cambridge, MA-based Biogen to upgrade its revenue growth forecast for this year to a range of 38% to 41%.
Tecfidera has quickly overtaken rivals--Novartis' ($NVS) Gilenya and Sanofi's ($SNY) Aubagio--racking up not only impressive sales but also an impressive safety record. A recent study by AdverseEvents found that it has the best safety record compared with its competitors.
Tecfidera came to the market with some impressive results from trials to support it. Late-stage trials showed Tecfidera could slash the annual relapse rate, stave off lesion growth and slow the march to disability. Biogen also initially priced Tecfidera at $54,900 per year, less than the $58,000 cost of Novartis' Gilenya. -- Eric Palmer (email | Twitter)
Germany gives an initial 'no additional benefit' on Biogen Idec's Tecfidera
Biogen hikes its forecast as zippy Tecfidera fuels big profits
Biogen MS blockbuster Tecfidera earns high marks for safety
J&J, GSK meds join Sovaldi, Tecfidera in blockbuster-to-be crowd
Biogen revenue leaps 50% on blockbuster-level Tecfidera sales